Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma. SENSEX 82,408.17 + 1,046.30. NIFTY 25,112.40 + 319. ...

Ousted Novo Nordisk CEO pays for investors’ inflated hopes Investor expectations, it seems, are harder to manage than blood sugar Lars Fruergaard Jørgensen has been ousted as chief executive of ...

Novo Nordisk (NVO-4.81%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.. As Reuters reports today, an online weight loss company ...

We're maintaining our Novo Nordisk fair value estimate at $89 per ADR. We expect Novo to gain $65 billion of a $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated look at NVO stock prospects.

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to fill a role that is almost never available: the winner will be only its ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has … ...

Novo Nordisk’s share price dropped more than 5 per cent in US pre-market trading as of around 2pm CEST. Go to accessibility shortcuts. Share this article Comments. Read more ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard Jørgensen is stepping down from the Danish drugmaker.

Novo Nordisk’s semaglutide drug is in a class of drugs known as GLP-1 agonists, which simulate a hormone that would naturally be released during digestion. Its drug, marketed as Ozempic, was ...

Year-to-date, both Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) delivered negative stock performance, at -26.5% and -6.7%, respectively.In recent years, these pharma giants have become even ...

On May 7th Novo cut its sales forecast for 2025, citing “lower-than-planned” growth in weight-loss drugs. S&P Global, a financial-data firm, expects sales of Lilly’s obesity drugs to ...